CoChat
Sign Up
Cited by 150Biosimilars and Bioanalytical MethodsMonoclonal and Polyclonal Antibodies ResearchProtein purification and stability

The DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.

Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins

Mahmood, Iftekhar, Green, Martin D·2005·Clinical Pharmacokinetics
DOI 10.2165/00003088-200544040-00001
Open this paper in CoChat — free account

Abstract

With an increasing number of therapeutic proteins moving into preclinical and clinical development, pharmacokinetic factors play an important role in the development of these macromolecules. It is also important that the pharmacokinetic evaluation of these compounds be done as accurately as possible. For macromolecules, evaluation of pharmacokinetic parameters is often complicated by a number of factors. Bioanalytical methods are essential for any pharmacokinetic study, but for many therapeutic proteins the immunoassay and bioassay methodologies are often nonspecific and sometimes the estimation of pharmacokinetic parameters becomes assay dependent. In vivo binding proteins, metabolites and antibody formation may also interfere with bioanalytical methodologies and thus may have significant impact on the pharmacokinetics of therapeutic proteins. There are also difficulties in identifying and quantifying metabolites as well as the binding of therapeutic proteins to endogenous proteins. Some macromolecules exhibit species specificity that complicates the preclinical pharmacological and toxicological evaluation of these compounds. Antibody formation is a particular problem in the preclinical evaluation of therapeutic proteins. Changes in structure or sequence of protein molecules (glycosylation or pegylation) may cause changes in the pharmacokinetics of these compounds. The size of therapeutic proteins may become a hindrance for absorption. Low absorption of intact molecules across biological membranes frequently occurs. Other factors that may affect the pharmacokinetics of a therapeutic protein are immunogenicity, presence of endogenous protein, time of drug administration, and rate and site of drug delivery. The relationship between pharmacokinetics and pharmacodynamics of therapeutic proteins is complex and in most cases is unclear. In many cases the mechanism and site of action are unknown for these compounds.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003088-200544040-00001

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 12

  1. Drickamer, 1998, Trends Biochem Sci, 23, 321, 10.1016/S0968-0004(98)01246-8 · DOI
  2. Ferraiolo, 1988, J Biol Response Mod, 7, 115
  3. Kurzrock, 1985, Cancer Res, 45, 2866
  4. Jones, 1990, J Am Soc Nephrol, 1, 400
  5. Lelchuk, 1985, Immunology, 56, 113
  6. Malik, 1991, Int J Exp Pathol, 72, A6
  7. Abdel-Razzak, 1993, Mol Pharmacol, 44, 707
  8. Kuwabara, 1995, J Pharmacol Exp Ther, 273, 1114
  9. Krigel, 1988, Cancer Res, 48, 3875
  10. Queseda, 1983, J Natl Cancer Inst, 70, 1041
  11. Rosenblum, 1985, Cancer Res, 45, 2421
  12. Furchgott, 1955, Pharmacol Rev, 7, 183

Cited by

Sorted by citations

See all 150

Related

See all

Metadata

Authors
Mahmood, I., & Green, M. D.
Affiliations
United States Food and Drug Administration (US)
Corresponding author
Mahmood, Iftekhar
ORCID
Mahmood, Iftekhar
Venue
Clinical Pharmacokinetics
Publisher
Springer Science and Business Media LLC
Published
2005
Volume
44
Issue
4
Pages
331-347
ISSN
0312-5963 (ISSN-L)
DOI
10.2165/00003088-200544040-00001
OpenAlex
W2038900628
Cited by
150
References
82
Citations by year
2026: 3 · 2025: 7 · 2024: 8 · 2023: 11 · 2022: 4 · 2021: 6 · 2020: 7 · 2019: 7 · 2017: 7 · 2016: 7 · 2015: 8 · 2014: 4 · 2013: 12 · 2012: 9
FWCI
0.48
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacokinetics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Keywords
therapeutic proteins, pharmacokinetics, pharmacodynamics, bioanalytical methods, immunoassay interference, protein binding, metabolite quantification, species specificity, antibody production, immunogenicity, glycosylation, PEGylation, protein absorption, drug delivery, preclinical evaluation
MeSH terms
Absorption, Drug Evaluation, Preclinical, Glycosylation, Humans, Kidney, Liver, Polyethylene Glycols, Proteins, Recombinant Proteins, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review